Quantessence Capital’s ClearPoint Neuro CLPT Stock Holding History

Quantessence Capital’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15,582	Closed	-$185K	–	235
2025 Q1	$185K	Buy	+15,582	New	+$242K	0.05%	284

Other funds holding CLPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return

Quantessence Capital's CLPT Position: Q2 2025 in Review

Quantessence Capital sold out of ClearPoint Neuro (CLPT) in Q2 2025, closing a stake of 15,582 shares — an estimated $185K sold.

Quantessence Capital first reported a position in CLPT in Q1 2025 and held it in 1 quarter. The position peaked at $185K in Q1 2025. 96 funds tracked by Wall St. Rank hold CLPT as of Q2 2025.

Quantessence Capital reported no remaining ClearPoint Neuro position as of Q2 2025 after selling out during the quarter.
Quantessence Capital sold 15,582 ClearPoint Neuro shares in Q2 2025, an estimated $185K.
Quantessence Capital first reported a position in ClearPoint Neuro in Q1 2025 and held it in 1 quarter.
Quantessence Capital's ClearPoint Neuro position peaked at $185K in Q1 2025.
96 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2025.

Based on Quantessence Capital's 13F filing for Q2 2025, filed 14 Aug 2025.